CSF markers related to pathogenetic mechanisms in Alzheimer's disease

Journal of Neural Transmission

Volumn 109, Issue 12, 2002, Pages 1491-1498

  Mulder, C ^a   Schoonenboom, S N M ^a   Wahlund, L O ^b   Scheltens, Ph ^a   Van Kamp, G J ^a   Veerhuis, R ^a   Hack, C E ^a   Blomberg, M ^b   Schutgens, R B H ^a   Eikelenboom, P ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

A beta (1 42); C1q; Pathogenic mechanism; SAP; Tau

Indexed keywords

AMYLOID BETA PROTEIN; BIOCHEMICAL MARKER; COMPLEMENT COMPONENT C1Q; SERUM AMYLOID P; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; COMPLEMENT C1Q; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; SERUM AMYLOID P-COMPONENT; SEVERITY OF ILLNESS INDEX; TAU PROTEINS;

EID: 0036921354     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00702-002-0763-y     Document Type: Article

References (22)

1. Arends YM, Duyckaerts C, Rozemuller JM, Eikelenbom P, Hauw J-J (2000) Microglia, amyloid and dementia in Alzheimer's disease. A correlative study. Neurobiol Aging 21: 39-47
2. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21: 383-421
3. Eikelenboom P, Veerhuis R (1996) The role of complement and activated microglia in the pathogenesis of Alzheimer's disease. Neurobiol Aging 17: 673-680
4. Emsley J, White HE, O'Hara BP, Oliva G, Srinivasan N, Tickle IJ, Blundell TL, Pepys MB, Wood SP (1994) Structure of pentameric human serum amyloid P component. Nature 367: 338-345
5. Familian A, Zwart B, Huisman HG, Rensink I, Roem D, Hordijk PL, Aarden LA, Hack CE (2001) Chromatin-independent binding of serum amyloid P component to apoptotic cells. J Immunol 167: 647-654.
6. Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, Miller B, Green R, Basherad R, Kertiles L, Boss MA, Seubert P (1998) High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 55: 937-945
7. Hawkins PN, Rossor MN, Gallimore JR, Miller B, Moore EG, Pepys MB (1994) Concentration of serum amyloid P component in the CSF as a possible marker of cerebral amyloid deposits in Alzheimer's disease. Biochem Biophys Res Commun 201: 722-726
8. Hoekzema R, Martens M, Brouwer MC, Hack CE (1988) The distortive mechanism for the activation of complement component C supported by the studies with a monoclonal antibody against the arms of C1q. Mol Immunol 25: 485-494
9. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, Bancher C, Cras P, Wiltfang J, Mehta PD, Iqbal K, Pottel H, Vanmechelen E, Vanderstichele H (1999) Improved discrimination of AD patients using β-amyloid (1-42) and tau levels in CSF. Neurology 52: 1555-1562
10. Kimura M, Asada T, Uno M, Machida N, Kasuya K, Taniguchi Y, Fujita T, Nishiyama E, Iwamoto N, Arai H (1999) Assessment of cerebrospinal fluid levels of serum amyloid P component in patients with Alzheimer's disease. Neurosci Lett 273: 137-139
11. Mayeux R, Saunders AM, Shea S, Mirra S, Evans D, Roses AD, Hyman BT, Crain B, Tang MX, Phelps CH (1998) Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. N Engl J Med 338: 506-511
12. Mc Geer E, Yasojima K, Schwab C, McGeer PL (2001) The pentraxins: Possible role in Alzheimer's disease and other innate inflammatory diseases. Neurobiol Aging 22: 843-848
13. Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD, Civin WH, Brachova L, Bradt B, Ward P, Lieberburg I (1992) Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci USA 89: 10016-10020
14. Rozemuller JM, Eikelenboom P, Stam FC, Beyreuter K, Masters CL (1989) A4 protein in Alzheimer's disease: Primary and secondary cellular events in extracellular amyloid deposition. J Neuropathol Exp Neurol 48: 647-691
15. Selkoe DJ (1999) Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399: A23-A31
16. Smyth MD, Cribbs DH, Tenner AJ, Shankle WR, Dick M, Kesslak JP, Cotman CW (1994) Decreased levels of C1q in cerebrospinal fluid of living Alzheimer patients correlate with disease state. Neurobiol Aging 15: 609-614
17. Tapiola T, Pirttila T, Mehta PD, Alafuoff I, Lehtovirta M, Soininen H (2000) Relationship between ApoE genotype and CSF beta-amyloid(1-42) and tau in patients with probable and definite Alzheimer's disease. Neurobiol Aging 21: 735-740
18. Vanderstichele H, Kerschaver van E, Hesse C, Davidsson P, Buyse M, Andreasen N, Minthon L, Wallin A, Blennow K, Vanmechelen E (2000) Standardization of measurement of β-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid: Int J Exp Clin Invest 7: 245-258
19. Vandermeeren M, Mercken M, Vanmechelen E, Six J, van de Voorde A, Martin JJ, Cras P (1993) Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwitch enzyme-linked immunosorbent assay. J Neurochem 61: 1828-1834
20. Xia W (2000) Role of presenilin in γ-secretase cleavage of amyloid precursor protein. Exp Gerontol 35: 453-460
21. Yasojima K, Schwab C, McGeer EG, McGeer PL (2001) Up-regulated production and activation of the complement system in Alzheimer's disease brain. Am J Pathol 154: 927-936
22. Zhan S-S, Veerhuis R, Kamphorst W, Eikelenboom P (1995) Distribution of beta-amyloid associated proteins in plaques in Alzheimer's disease and in non-demented elderly. Neurodegeneration 4: 219-297